PICCOLO: An Open-Label, Single-Arm, Phase 2 Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian Cancers With High Folate Receptor Alpha Expression
IMMUNOGEN IS NOW PART OF ABBVIE
Together we will be working to make a remarkable impact for cancer patients and their communities of care, raising standards of care and advancing a dynamic oncology pipeline.